OMEROS CORP Basic Shares Outstanding (Weighted Average)
OMEROS CORP (OMER) reported Basic Shares Outstanding (Weighted Average) of 72.13 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- OMEROS CORP weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 72.13M shares, a 23.12% increase year-over-year.
- OMEROS CORP weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 71.92M shares, a 23.87% increase year-over-year.
- OMEROS CORP weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 70.89M shares, a 22.25% increase year-over-year.
- OMEROS CORP weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 66.26M shares, a 14.35% increase year-over-year.
- OMEROS CORP weighted average number of shares outstanding, basic for fiscal 2025 was 63.51M shares, a 9.18% increase from fiscal 2024.
- OMEROS CORP weighted average number of shares outstanding, basic for fiscal 2024 was 58.17M shares, a 7.28% decline from fiscal 2023.
- OMEROS CORP weighted average number of shares outstanding, basic for fiscal 2023 was 62.74M shares, a 0.00% increase from fiscal 2022.
- OMEROS CORP weighted average number of shares outstanding, basic for fiscal 2022 was 62.74M shares, a 0.63% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 72.13M shares 10-Q · filed 2026-08-12 | 72.03M shares 10-Q · filed 2026-08-12 | 71.65M shares derived: average of 3 quarters · filed 2026-08-12 | 70.30M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 71.92M shares 10-Q · filed 2026-05-13 | 71.40M shares derived: average of 2 quarters · filed 2026-05-13 | 69.69M shares derived: average of 3 quarters · filed 2026-05-13 | 66.91M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 70.89M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 68.58M shares derived: average of 2 quarters · filed 2026-03-31 | 65.25M shares derived: average of 3 quarters · filed 2026-08-12 | 63.51M shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 66.26M shares 10-Q · filed 2025-11-13 | 62.42M shares derived: average of 2 quarters · filed 2026-08-12 | 61.05M shares 10-Q · filed 2025-11-13 | 60.22M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 58.59M shares 10-Q · filed 2026-08-12 | 58.32M shares 10-Q · filed 2026-08-12 | 58.21M shares derived: average of 3 quarters · filed 2026-08-12 | 58.14M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 58.06M shares 10-Q · filed 2026-05-13 | 58.02M shares derived: average of 2 quarters · filed 2026-05-13 | 58.00M shares derived: average of 3 quarters · filed 2026-05-13 | 57.98M shares derived: average of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | 57.99M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 57.97M shares derived: average of 2 quarters · filed 2026-03-31 | 57.96M shares derived: average of 3 quarters · filed 2026-03-31 | 58.17M shares 10-K · filed 2026-03-31 |
| 2024-09-30 | 57.95M shares 10-Q · filed 2025-11-13 | 57.95M shares derived: average of 2 quarters · filed 2025-11-13 | 58.23M shares 10-Q · filed 2025-11-13 | 59.28M shares derived: average of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | 57.94M shares 10-Q · filed 2025-08-14 | 58.37M shares 10-Q · filed 2025-08-14 | 59.73M shares derived: average of 3 quarters · filed 2026-03-31 | 60.51M shares derived: average of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | 58.80M shares 10-Q · filed 2025-05-15 | 60.62M shares derived: average of 2 quarters · filed 2026-03-31 | 61.36M shares derived: average of 3 quarters · filed 2026-03-31 | 61.73M shares derived: average of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | 62.43M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 62.65M shares derived: average of 2 quarters · filed 2026-03-31 | 62.71M shares derived: average of 3 quarters · filed 2026-03-31 | 62.74M shares 10-K · filed 2026-03-31 |
| 2023-09-30 | 62.86M shares 10-Q · filed 2024-11-13 | 62.85M shares derived: average of 2 quarters · filed 2024-11-13 | 62.84M shares 10-Q · filed 2024-11-13 | 62.82M shares derived: average of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | 62.84M shares 10-Q · filed 2024-08-07 | 62.83M shares 10-Q · filed 2024-08-07 | 62.81M shares derived: average of 3 quarters · filed 2025-03-31 | 62.79M shares derived: average of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | 62.83M shares 10-Q · filed 2024-05-15 | 62.80M shares derived: average of 2 quarters · filed 2025-03-31 | 62.77M shares derived: average of 3 quarters · filed 2025-03-31 | 62.76M shares derived: average of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | 62.76M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 62.75M shares derived: average of 2 quarters · filed 2025-03-31 | 62.74M shares derived: average of 3 quarters · filed 2025-03-31 | 62.74M shares 10-K · filed 2025-03-31 |
| 2022-09-30 | 62.73M shares 10-Q · filed 2023-11-09 | 62.73M shares derived: average of 2 quarters · filed 2023-11-09 | 62.73M shares 10-Q · filed 2023-11-09 | 62.69M shares derived: average of 4 quarters · filed 2024-04-01 |
| 2022-06-30 | 62.73M shares 10-Q · filed 2023-08-09 | 62.73M shares 10-Q · filed 2023-08-09 | 62.68M shares derived: average of 3 quarters · filed 2024-04-01 | 62.63M shares derived: average of 4 quarters · filed 2024-04-01 |
| 2022-03-31 | 62.72M shares 10-Q · filed 2023-05-09 | 62.65M shares derived: average of 2 quarters · filed 2024-04-01 | 62.60M shares derived: average of 3 quarters · filed 2024-04-01 | 62.55M shares derived: average of 4 quarters · filed 2024-04-01 |
| 2021-12-31 | 62.57M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | 62.54M shares derived: average of 2 quarters · filed 2024-04-01 | 62.49M shares derived: average of 3 quarters · filed 2024-04-01 | 62.34M shares 10-K · filed 2024-04-01 |
| 2021-09-30 | 62.51M shares 10-Q · filed 2022-11-09 | 62.44M shares derived: average of 2 quarters · filed 2022-11-09 | 62.27M shares 10-Q · filed 2022-11-09 | 62.12M shares derived: average of 4 quarters · filed 2023-03-13 |
| 2021-06-30 | 62.37M shares 10-Q · filed 2022-08-09 | 62.15M shares 10-Q · filed 2022-08-09 | 61.99M shares derived: average of 3 quarters · filed 2023-03-13 | 61.05M shares derived: average of 4 quarters · filed 2023-03-13 |
| 2021-03-31 | 61.93M shares 10-Q · filed 2022-05-10 | 61.79M shares derived: average of 2 quarters · filed 2023-03-13 | 60.61M shares derived: average of 3 quarters · filed 2023-03-13 | 59.08M shares derived: average of 4 quarters · filed 2023-03-13 |
| 2020-12-31 | 61.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | 59.95M shares derived: average of 2 quarters · filed 2023-03-13 | 58.14M shares derived: average of 3 quarters · filed 2023-03-13 | 57.18M shares 10-K · filed 2023-03-13 |
| 2020-09-30 | 58.23M shares 10-Q · filed 2021-11-09 | 56.37M shares derived: average of 2 quarters · filed 2021-11-09 | 55.68M shares 10-Q · filed 2021-11-09 | |
| 2020-06-30 | 54.51M shares 10-Q · filed 2021-08-09 | 54.41M shares 10-Q · filed 2021-08-09 | ||
| 2019-12-31 | 49.52M shares 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |